Cedarburg Hauser expands in APIs
Reactor capacity 50% up as demand grows
Cedarburg Hauser Pharmaceuticals, a US-based CMO active in small molecule APIs and pharmaceutical intermediates, has expanded its API facility in Wisconsin. This has seen a nearly 50% increase in total reactor capacity, plus the addition of a reactor and chiller that allow for cryogenic reactions in the GMP laboratories.
All this came in response to increased demand for commercial API manufacture, the company said. In addition to the new reactors, Cedarburg Hauser has made improvements to the air handling systems in the GMP manufacturing suites, installed a reverse osmosis water system, improved its isolation capabilities and upgraded its Emerson DeltaV Digital Automation System.